On the use of herbal medicines in management of inflammatory bowel diseases: A systematic review of animal and human studies

Digestive Diseases and Sciences

Volumn 54, Issue 3, 2009, Pages 471-480

  Rahimi, Roja ^a   Mozaffari, Shilan ^a   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Herbal therapies; Inflammatory bowel disease; Mechanisms

Indexed keywords

2,3,5,4' TETRAHYDROXYSTILBENE 2 O BETA DEXTRO GLUCOSIDE; ACETYL 11 OXO BETA BOSWELLIC ACID; ANGELICA SINENSIS EXTRACT; BOSWELLIC ACID; CATALPOSIDE; CURCUMIN; ESSENTIAL OIL; GINKGO BILOBA EXTRACT; GLUCOSIDASE; GUGGULSTERONE; HERBACEOUS AGENT; LEUKOTRIENE; NICOTIANA TOBACUM EXTRACT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA 3 FATTY ACID; PHENYLETHANOID ACTEOSIDE; PLACEBO; PLANT EXTRACT; PLANT GLYCOSIDE; POLYSACCHARIDE; PRIMROSE OIL; THEAFLAVIN 3,3' DIGALLATE; THEARUBIGIN; TRIPTERYGIUM WILFORDII EXTRACT; TRYPTANTHRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZATARIA MULTIFLORA EXTRACT; ZERUMBONE; ZIZIPHORA CLINOPOIDES EXTRACT;

ALOE VERA; ALTERNATIVE MEDICINE; ANGELICA SINENSIS; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ARTEMISIA ABSINTHIUM; BOSWELLIA; BOSWELLIA SERRATA; CATALPA OVATA; CLINICAL TRIAL; COLITIS; COMMIPHORA; CROHN DISEASE; CURCUMA LONGA; DRUG MECHANISM; ENTERITIS; EVENING PRIMROSE; GARDENIA JASMINOIDES; GINKGO BILOBA; HELPER CELL; HERBAL MEDICINE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; INNATE IMMUNITY; MEDICINAL PLANT; NICOTIANA TOBACUM; NONHUMAN; OXIDATIVE STRESS; PISTACIA LENTISCUS; PLANTAGO OVATA; PLATAGO LANCEOLATA; POLYGONUM MULTIFLORUM; POLYGONUM TINCTORIUM; PRIORITY JOURNAL; REVIEW; RHEUM TANGUTICUM; SATUREJA KHUZESTANICA; TEA; THROMBOCYTE AGGREGATION INHIBITION; TRYPTERIGIUM WILFORDII; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; WHEAT; ZATARIA MULTIFLORA; ZINGIBER ZERUMBET; ZIZIPHORA CLINOPOIDES;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HUMANS; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASES; LEUKOTRIENE B4; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHYTOTHERAPY; PLANT PREPARATIONS; PLATELET AGGREGATION INHIBITORS;

EID: 59449103434     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0368-x     Document Type: Review

References (83)

1. A Rezaie RD Parker M Abdollahi 2007 Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 52 2015 2021 10.1007/s10620-006-9622-2
2. G Trallori D Palli C Saieva G Bardazzi AG Bonanomi G d'Albasio 1996 A population-based study of inflammatory bowel disease in Florence over 15 years (1978-1992) Scand J Gastroenterol 31 892 899 10.3109/00365529609051998
3. R Rahimi S Nikfar B Larijani M Abdollahi 2005 A review on the role of antioxidants in the management of diabetes and its complications Biomed Pharmacother 59 365 373 10.1016/j.biopha.2005.07.002
4. J Treasure 2005 Herbal medicine and cancer: an introductory overview Semin Oncol Nurs 21 177 183 10.1016/j.soncn.2005.04.006
5. F Stickel D Schuppan 2007 Herbal medicine in the treatment of liver diseases Dig Liver Dis 39 293 304 10.1016/j.dld.2006.11.004
6. P Salari A Rezaie B Larijani M Abdollahi 2008 A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis Med Sci Monit 14 RA37 RA44
7. L Langmead DS Rampton 2006 Review article: complementary and alternative therapies for inflammatory bowel disease Aliment Pharmacol Ther 23 341 349 10.1111/j.1365-2036.2006.02761.x
8. M Bensoussan N Jovenin B Garcia L Vandromme D Jolly O Bouché 2006 Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey Gastroenterol Clin Biol 30 14 23 10.1016/S0399-8320(06)73072-X
9. J Langhorst IB Anthonisen U Steder-Neukamm R Lüdtke G Spahn A Michalsen 2005 Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey Inflamm Bowel Dis 11 287 295 10.1097/01.MIB.0000160771.71328.6c
10. RJ Hilsden MJ Verhoef A Best G Pocobelli 2003 Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey Am J Gastroenterol 98 1563 1568 10.1111/j.1572-0241.2003.07519.x
11. AS Day KE Whitten TD Bohane 2004 Use of complementary and alternative medicines by children and adolescents with inflammatory bowel disease J Paediatr Child Health 40 681 684 10.1111/j.1440-1754.2004.00510.x
12. M Kaplan EA Mutlu M Benson JZ Fields A Banan A Keshavarzian 2007 Use of herbal preparations in the treatment of oxidant-mediated inflammatory disorders Complement Ther Med 15 207 216 10.1016/j.ctim.2006.06.005
13. T Kucharzik C Maaser A Lügering M Kagnoff L Mayer S Targan 2006 Recent understanding of IBD pathogenesis: implications for future therapies Inflamm Bowel Dis 12 1068 1083 10.1097/01.mib.0000235827.21778.d5
14. SJ Brown L Mayer 2007 The immune response in inflammatory bowel disease Am J Gastroenterol 102 2058 2069 10.1111/j.1572-0241.2007.01343.x
15. F Scaldaferri C Fiocchi 2007 Inflammatory bowel disease: progress and current concepts of etiopathogenesis J Dig Dis 8 171 178 10.1111/j.1751-2980. 2007.00310.x
16. U Elsässer-Beile S von Kleist S Gerlach H Gallati JS Mönting 1994 Cytokine production in whole blood cell cultures of patients with Crohn's disease and ulcerative colitis J Clin Lab Anal 8 447 451 10.1002/jcla.1860080618
17. CW Marano SA Lewis AP Garulacan LA Soler JM Mullin 1998 Tumor necrosis factor-α increases sodium and chloride conductance across the tight junction of CACO-2 BBE, a human intestinal epithelial cell line J Membr Biol 161 263 274 10.1007/s002329900333
18. R Rahimi S Nikfar M Abdollahi 2007 Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids Med Sci Monit 13 PI13 PI18
19. R Rahimi S Nikfar M Abdollahi 2007 Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials Biomed Pharmacother 61 75 80 10.1016/j.biopha.2006.06.022
20. A Rezaie B Taghavi Bayat M Abdollahi 2005 Biologic management of fistulizing Crohn's disease Int J Pharmacol 1 17 24
21. M Zhang CS Deng JJ Zheng J Xia 2006 Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis Acta Pharmacol Sin 27 1071 1077 10.1111/j.1745-7254.2006.00322.x
22. H Jiang CS Deng M Zhang J Xia 2006 Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2 World J Gastroenterol 12 3848 3853
23. YT Jian GF Mai JD Wang YL Zhang RC Luo YX Fang 2005 Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid World J Gastroenterol 11 1747 1752
24. YT Jian JD Wang GF Mai YL Zhang ZS Lai 2004 Modulation of intestinal mucosal inflammatory factors by curcumin in rats with colitis Di Yi Jun Yi Da Xue Xue Bao 24 1353 1358
25. K Sugimoto H Hanai K Tozawa T Aoshi M Uchijima T Nagata 2002 Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice Gastroenterology 123 1912 1922 10.1053/gast.2002.37050
26. J Ren Q Tao X Wang Z Wang J Li 2007 Efficacy of T2 in active Crohn's disease: a prospective study report Dig Dis Sci 52 1790 1797 10.1007/s10620-007-9747-y
27. AC Kaliora MG Stathopoulou JK Triantafillidis GV Dedoussis NK Andrikopoulos 2007 Chios mastic treatment of patients with active Crohn's disease World J Gastroenterol 13 748 753 10.3748/wjg.13.6031
28. X Wang L Zhao T Han S Chen J Wang 2008 Protective effects of 2, 3, 5, 4′-tetrahydroxystilbene-2-O-beta-d-glucoside, an active component of Polygonum multiflorum Thunb, on experimental colitis in mice Eur J Pharmacol 578 339 348 10.1016/j.ejphar.2007.09.013
29. LA Nakhai A Mohammadirad N Yasa B Minaie S Nikfar G Ghazanfari 2007 Benefits of Zataria multiflora Boiss in experimental model of mouse inflammatory bowel disease Evid Based Complement Alternat Med 4 43 50 10.1093/ecam/nel051
30. M Hausmann F Obermeier DH Paper K Balan N Dunger K Menzel 2007 In vivo treatment with the herbal phenylethanoid acetonide ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis Clin Exp Immunol 148 373 381
31. Y Deguchi A Andoh O Inatomi Y Yagi S Bamba Y Araki 2007 Curcumin prevents the development of dextran sulfate sodium (DSS)-induced experimental colitis Dig Dis Sci 52 2993 2998 10.1007/s10620-006-9138-9
32. L Camacho-Barquero I Villegas JM Sánchez-Calvo E Talero S Sánchez-Fidalgo V Motilva 2007 Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis Int Immunopharmacol 7 333 342 10.1016/j.intimp. 2006.11.006
33. H Ghafari N Yasa A Mohammadirad G Dehghan MJ Zamani S Nikfar 2006 Protection by Ziziphora clinopoides of acetic acid-induced toxic bowel inflammation through reduction of cellular lipid peroxidation and myeloperoxidase activity Hum Exp Toxicol 25 325 332 10.1191/0960327105ht626oa
34. G Ghazanfari B Minaie N Yasa L Nakhai A Mohammadirad S Nikfar 2006 Biochemical and histopathological evidences for beneficial effects of Satureja Khuzestanica Jamzad essential oil on the mouse model of inflammatory bowel diseases Toxicol Mech Methods 16 365 372 10.1080/15376520600620125
35. YH Zhou JP Yu YF Liu XJ Teng M Ming P Lv 2006 Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-alpha, NF-kappaBp65, IL-6) in TNBS-induced colitis in rats Mediators Inflamm 92642 2006
36. M Zhang C Deng J Zheng J Xia D Sheng 2006 Curcumin inhibits trinitrobenzene sulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma Int Immunopharmacol 6 1233 1242 10.1016/j.intimp. 2006.02.013
37. A Mustafa A El-Medany HH Hagar G El-Medany 2006 Ginkgo biloba attenuates mucosal damage in a rat model of ulcerative colitis Pharmacol Res 53 324 330 10.1016/j.phrs.2005.12.010
38. PS Oh KT Lim 2006 Plant originated glycoprotein has anti-oxidative and anti-inflammatory effects on dextran sulfate sodium-induced colitis in mouse J Biomed Sci 13 549 560 10.1007/s11373-006-9083-9
39. JH Cheon JS Kim JM Kim N Kim HC Jung IS Song 2006 Plant sterol guggulsterone inhibits nuclear factor-kappaB signaling in intestinal epithelial cells by blocking IkappaB kinase and ameliorates acute murine colitis Inflamm Bowel Dis 12 1152 1161 10.1097/01.mib.0000235830.94057.c6
40. A Ukil S Maity PK Das 2006 Protection from experimental colitis by theaflavin-3, 3′-digallate correlates with inhibition of IKK and NF-kappaB activation Br J Pharmacol 149 121 131 10.1038/sj.bjp. 0706847
41. C Anthoni MG Laukoetter E Rijcken T Vowinkel R Mennigen S Müller 2006 Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis Am J Physiol Gastrointest Liver Physiol 290 G1131 G1137 10.1152/ajpgi.00562.2005
42. JK Ko CH Cho 2005 The diverse actions of nicotine and different extracted fractions from tobacco smoke against hapten-induced colitis in rats Toxicol Sci 87 285 295 10.1093/toxsci/kfi238
43. PR Kiela AJ Midura N Kuscuoglu SD Jolad AM Sólyom DG Besselsen 2005 Effects of Boswellia serrata in mouse models of chemically induced colitis Am J Physiol Gastrointest Liver Physiol 288 G798 G808 10.1152/ajpgi.00433.2004
44. SW Kim SC Choi EY Choi KS Kim JM Oh HJ Lee 2004 Catalposide, a compound isolated from Catalpa ovata, attenuates induction of intestinal epithelial proinflammatory gene expression and reduces the severity of trinitrobenzene sulfonic acid-induced colitis in mice Inflamm Bowel Dis 10 564 572 10.1097/00054725-200409000-00010
45. A Murakami R Hayashi T Tanaka KH Kwon H Ohigashi R Safitri 2003 Suppression of dextran sodium sulfate-induced colitis in mice by zerumbone, a subtropical ginger sesquiterpene, and nimesulide: separately and in combination Biochem Pharmacol 66 1253 1261 10.1016/S0006-2952(03)00446-5
46. S Maity A Ukil S Karmakar N Datta T Chaudhuri JR Vedasiromoni 2003 Thearubigin, the major polyphenol of black tea, ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis Eur J Pharmacol 30 470 103 112 10.1016/S0014-2999(03)01760-6
47. A Ukil S Maity S Karmakar N Datta JR Vedasiromoni PK Das 2003 Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis Br J Pharmacol 139 209 218 10.1038/sj.bjp. 0705241
48. MJ Micallef K Iwaki T Ishihara S Ushio M Aga T Kunikata 2002 The natural plant product tryptanthrin ameliorates dextran sodium sulfate-induced colitis in mice Int Immunopharmacol 2 565 578 10.1016/S1567-5769(01)00206-5
49. CF Krieglstein C Anthoni EJ Rijcken M Laukötter HU Spiegel SE Boden 2001 Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis Int J Colorectal Dis 16 88 95 10.1007/s003840100292
50. B Omer S Krebs H Omer TO Noor 2007 Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study Phytomedicine 14 87 95 10.1016/j.phymed.2007.01.001
51. L Langmead RM Feakins S Goldthorpe H Holt E Tsironi A De Silva 2004 Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis Aliment Pharmacol Ther 19 739 747 10.1111/j.1365-2036. 2004.01902.x
52. WG Dong SP Liu HH Zhu HS Luo JP Yu 2004 Abnormal function of platelets and role of Angelica sinensis in patients with ulcerative colitis World J Gastroenterol 10 606 609
53. E Ben-Arye E Goldin D Wengrower A Stamper R Kohn E Berry 2002 Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial Scand J Gastroenterol 37 444 449 10.1080/003655202317316088
54. I Gupta A Parihar P Malhotra S Gupta R Lüdtke H Safayhi 2001 Effects of gum resin of Boswellia serrata in patients with chronic colitis Planta Med 67 391 395 10.1055/s-2001-15802
55. H Gerhardt F Seifert P Buvari H Vogelsang R Repges 2001 Therapy of active Crohn disease with Boswellia serrata extract H 15 Z Gastroenterol 39 1 11 17 10.1055/s-2001-10708
56. F Fernández-Bañares J Hinojosa JL Sánchez- Lombraña E Navarro JF Martínez-Salmerón A García-Pugés 1999 Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish group for the study of Crohn's disease and ulcerative colitis (GETECCU Am J Gastroenterol 94 427 433
57. I Gupta A Parihar P Malhotra GB Singh R Lüdtke H Safayhi 1997 Effects of Boswellia serrata gum resin in patients with ulcerative colitis Eur J Med Res 2 1 37 43
58. SM Greenfield AT Green JP Teare AP Jenkins NA Punchard CC Ainley 1993 A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis Aliment Pharmacol Ther 7 159 166
59. A Rezaie F Ghorbani A Eshghtork MJ Zamani G Dehghan B Taghavi 2006 Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-beta 1 in relation to disease activity in Crohn's disease patients Ann N Y Acad Sci 1091 110 122 10.1196/annals.1378.060
60. G Jahanshahi V Motavasel A Rezaie AA Hashtroudi NE Daryani M Abdollahi 2004 Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases Dig Dis Sci 49 1752 1757 10.1007/s10620-004-9564-5
61. L Liu ZP Wang CT Xu BR Pan QB Mei Y Long 2003 Effects of Rheum tanguticum polysaccharide on TNBS-induced colitis and CD4+T cells in rats World J Gastroenterol 9 2284 2288
62. L Liu QB Mei SY Zhou FH Han Y Long JY Liu 2003 Effects of tanguticum maxim polysaccharide on ulcerative colitis induced by TNBS in rats Zhongguo Zhong Yao Za Zhi 28 246 249
63. AW Ford-Hutchinson JF Evans 1986
64. P Sharon WF Stenson 1984 Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease Gastroenterology 86 453 460
65. W Kruis 2004 Review article: antibiotics and probiotics in inflammatory bowel disease Aliment Pharmacol Ther 20 75 78 10.1111/j.1365-2036.2004.02051.x
66. RB Sartor 2003 Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when Curr Opin Gastroenterol 19 358 365
67. A Swidsinski A Ladhoff A Pernthaler S Swidsinski V Loening-Baucke M Ortner 2002 Mucosal flora in inflammatory bowel disease Gastroenterology 122 44 54 10.1053/gast.2002.30294
68. R Rahimi S Nikfar A Rezaie M Abdollahi 2006 A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease Clin Ther 28 1983 1988 10.1016/j.clinthera.2006.12.012
69. R Rahimi S Nikfar A Rezaie M Abdollahi 2007 A meta-analysis of antibiotic therapy for active ulcerative colitis Dig Dis Sci 52 2920 2925 10.1007/s10620-007-9760-1
70. A Kumar Y Takada AM Boriek BB Aggarwal 2004 Nuclear factor-kappaB: its role in health and disease J Mol Med 82 434 448 10.1007/s00109-004-0555-y
71. LJ Egan M Toruner 2006 NF-kappaB signaling: pros and cons of altering NF-kappaB as a therapeutic approach Ann N Y Acad Sci 1072 114 122 10.1196/annals.1326.009
72. S Schreiber S Nikolaus J Hampe 1998 Activation of nuclear factor kappa B inflammatory bowel disease Gut 42 477 484
73. L Andresen VL Jørgensen A Perner A Hansen J Eugen-Olsen J Rask-Madsen 2005 Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis Gut 54 503 509 10.1136/gut.2003.034165
74. Y Yamamoto RB Gaynor 2004 IkappaB kinases: key regulators of the NF-kappaB pathway Trends Biochem Sci 29 72 79 10.1016/j.tibs.2003.12.003
75. MC Martín A Martinez JL Mendoza C Taxonera M Díaz-Rubio M Fernández-Arquero 2007 Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility Immunogenetics 59 833 837 10.1007/s00251-007-0255-1
76. JO Lundberg PM Hellström JM Lundberg K Alving 1994 Greatly increased luminal nitric oxide in ulcerative colitis Lancet 344 1673 1674 10.1016/S0140-6736(94)90460-X
77. A Rezaie S Khalaj M Shabihkhani S Nikfar MJ Zamani A Mohammadirad 2007 Study on the correlations among disease activity index and salivary transforming growth factor-beta 1 and nitric oxide in ulcerative colitis patients Ann N Y Acad Sci 1095 305 314 10.1196/annals.1397.034
78. U Mahadevan EV Loftus Jr WJ Tremaine WJ Sandborn 2002 Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease Am J Gastroenterol 97 910 914 10.1111/j.1572-0241.2002.05608.x
79. Y Miedany S Youssef I Ahmed M El Gaafary 2006 The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases Am J Gastroenterol 101 311 317 10.1111/j.1572-0241. 2006.00384.x
80. I Talstad K Rootwelt E Gjone 1973 Thrombocytosis in ulcerative colitis and Crohn's disease Scand J Gastroenterol 8 135 138
81. AM Lake JQ Stauffer MJ Stuart 1978 Hemostatic alterations in inflammatory bowel disease: response to therapy Am J Dig Dis 23 897 902 10.1007/BF01072463
82. CE Collins DS Rampton 1997 Review article: platelets in inflammatory bowel disease-pathogenetic role and therapeutic implications Aliment Pharmacol Ther 11 237 247 10.1046/j.1365-2036.1997.153328000.x
83. SC Pitchford 2007 Novel uses for anti-platelet agents as anti-inflammatory drugs Br J Pharmacol 152 987 1002 10.1038/sj.bjp. 0707364